Any kind of heart problem in dogs can cause lot of discomfort and even shorten their life.
To prevent congestive heart failure in dogs and improve the functions of the heart, Vetmedin 1.25 mg, 50 Chewable Tablets for dogs is very effective.
Vetmedin 1.25 mg, 50 Chewable Tablets is a pimobendan medication effective for treatment of some types of congestive heart failure in dogs.
This chewable dog medicine by BOEHRINGER INGELHEIM VETMEDICA, INC. improves blood flow to and from the heart and reduces stress on the organ, which in turn improves the condition of the heart.
Dogs with congestive heart failure that are treated with Vetmedin 1.25 mg pet medicine have improved quality of life and increased life expectancy.
You can order the best quality heart medicine for dogs and other dog medications and prescribed pet medications online from our Texas pet drugs online. We care for your pets!
This heart medicine for dogs is approved by FDA for oral use in dogs only.
Federal law restricts this pet medicine to use by or on the order of a licensed veterinarian.
- Improves quality of life after congestive heart failure in dogs.
- Contains pimobendan which improves the efficiency of your dog’s heart
- Increases the heart’s ability to contract and widens blood vessels around it.
- Improves blood flow to and from the heart.
This pet drug is supplied as oblong half-scored chewable tablets containing 1.25 or 5 mg pimobendan per tablet. Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic drug having vasodilatative properties.
Pimobendan exerts a stimulatory myocardial effect by a dual mechanism of action consisting of an increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (Type III). Pimobendan exhibits vasodilating activity by inhibiting phosphodiesterase III activity.
Vetmedin (pimobendan) is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM). Vetmedin is indicated for use with concurrent therapy for congestive heart failure in dogs as appropriate on a case-by-case basis.
- A dog with modified New York Heart Association (NYHA) Class II heart failure has fatigue, shortness of breath, coughing, etc. apparent when ordinary exercise is exceeded.
- A dog with modified NYHA Class III heart failure is comfortable at rest, but exercise capacity is minimal.
- A dog with modified NYHA Class IV heart failure has no capacity for exercise and disabling clinical signs are present even at rest.
Dosage and Administration:
Vetmedin pet med should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening).
The chewable tablets for dogs are scored and the calculated dosage should be provided to the nearest half tablet increment.
Vetmedin, heart medicine for dogs should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
This oral pet medication is only for use in dogs with clinical evidence of heart failure. At 3 and 5 times the recommended dosage, administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology.
Not for use in humans. Keep this and all pet medications out of reach of children. Consult a physician in case of accidental ingestion by humans.
The safety of Vetmedin pet medications has not been established in dogs with asymptomatic heart disease or in heart failure in dogs caused by etiologies other than atrioventricular valvular insufficiency AVVI or DCM. The safe use of Vetmedin pet med has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.
Clinical findings/adverse reactions were recorded in a 56-day field study of dogs with congestive heart failure (CHF) due to atrioventricular valvular insufficiency AVVI (256 dogs) or DCM (99 dogs). Dogs were treated with either Vetmedin pet medications (175 dogs) or the active control enalapril maleate (180 dogs). Dogs in both treatment groups received additional background cardiac therapy.
The Vetmedin group had the following prevalence (percent of dogs with at least one occurrence) of common adverse reactions/new clinical findings (not present in a dog prior to beginning study treatments): poor appetite (38%), lethargy (33%), diarrhea (30%), dyspnea (29%), azotemia (14%), weakness and ataxia (13%), pleural effusion (10%), syncope (9%), cough (7%), sudden death (6%), ascites (6%), and heart murmur (3%).
Prevalence was similar in the active control group.
The prevalence of renal failure was higher in the active control group (4%) compared to the Vetmedin pet med group (1%).
Adverse reactions/new clinical findings were seen in both treatment groups and were potentially related to CHF, the therapy of CHF, or both. The following adverse reactions/new clinical findings are listed according to body system and are not in order of prevalence: CHF death, sudden death, chordae tendineae rupture, left atrial tear, arrhythmias overall, tachycardia, syncope, weak pulses, irregular pulses, increased pulmonary edema, dyspnea, increased respiratory rate, coughing, gagging, pleural effusion, ascites, hepatic congestion, decreased appetite, vomiting, diarrhea, melena, weight loss, lethargy, depression, weakness, collapse, shaking, trembling, ataxia, seizures, restlessness, agitation, pruritus, increased water consumption, increased urination, urinary accidents, azotemia, dehydration, abnormal serum electrolyte, protein, and glucose values, mild increases in serum hepatic enzyme levels, and mildly decreased platelet counts.
CHF Death and New Arrhythmias in the 56-Day Field Study
|Vetmedin®Group||Active Control Group|
|Dogs that died due to CHF||80.7% n = 134|
88 of 101 dogs with AVVI
16 of 49 dogs with DCM
|76.3% n = 131|
77 of 100 dogs with AVVI
10 of 50 dogs with DCM
|Dogs that developed new arrhythmiasa||9.4% n = 175|
45 of 126 dogs with AVVI
24 of 49 dogs with DCM
|45.0% n = 180|
59 of 130 dogs with AVVI
22 of 50 dogs with DCM
New arrhythmias included supraventricular premature beats and tachycardia, atrial fibrillation, atrioventricular block, sinus bradycardia, ventricular premature beats and tachycardia, and bundle branch block.
Following the 56-day masked field study, 137 dogs in the Vetmedin pet medicine group were allowed to continue on Vetmedin in an open-label extended-use study without restrictions on concurrent therapy. The adverse reactions/new clinical findings in the extended-use study were consistent with those reported in the 56-day study, with the following exception: One dog in the extended-use study developed acute cholestatic liver failure after 140 days on Vetmedin and furosemide.
In foreign post-approval drug experience reporting, the following additional suspected adverse reactions were reported in dogs treated with a capsule formulation of pimobendan: hemorrhage, petechia, anemia, hyperactivity, excited behavior, erythema, rash, drooling, constipation, and diabetes mellitus.
To report suspected adverse reactions, to obtain a Material Safety Data Sheet, or for technical assistance call 1-866-638-2226.
In a double-masked, multi-site, 56-day field study, 355 dogs with modified NYHA Class II, III, or IV CHF due to AVVI or DCM were randomly assigned to either the active control (enalapril maleate) or the Vetmedin pet med treatment group. Of the 355 dogs, 52% were male and 48% were female; 72% were diagnosed with atrioventricular valvular insufficiency AVVI and 28% were diagnosed with DCM; 34% had Class II, 47% had Class III, and 19% had Class IV CHF. Dogs ranged in age and weight from 1 to 17 years and 3.3 to 191 lb, respectively. The most common breeds were mixed breed, Doberman pinscher, Cocker Spaniel, Miniature/Toy Poodle, Maltese, Chihuahua, Miniature Schnauzer, Dachshund, and Cavalier King Charles Spaniel. The 180 dogs (130 AVVI, 50 DCM) in the active control group received enalapril maleate (0.5 mg/kg once or twice daily), and all but 2 received furosemide. Per protocol, all dogs with DCM in the active control group received digoxin. The 175 dogs (126 AVVI, 49 DCM) in the Vetmedin group received pimobendan (0.5 mg/kg/day divided into 2 portions that were not necessarily equal, and the portions were administered approximately 12 hours apart), and all but 4 received furosemide. Digoxin was optional for treating supra ventricular tachyarrhythmia in either treatment group, as was the addition of a β-adrenergic blocker if digoxin was ineffective in controlling heart rate. After initial treatment with this pet medicine at the clinic on Day 1, dog owners were to administer the assigned product and concurrent medications for up to 56±4 days. The determination of effectiveness (treatment success) for each case was based on improvement in at least 2 of the 3 following primary variables: modified NYHA classification, pulmonary edema score by a masked veterinary radiologist, and the investigator’s overall clinical effectiveness score (based on physical examination, radiography, electrocardiography, and clinical pathology). Attitude, pleural effusion, coughing, activity level, furosemide dosage change, cardiac size, body weight, survival, and owner observations were secondary evaluations contributing information supportive to product effectiveness and safety.
Based on protocol compliance and individual case integrity, 265 cases (134 Vetmedin, 131 active controls) were evaluated for treatment success on Day 29.
Effectiveness Results for the 56-Day Field Study
|Vetmedin®Group||Active Control Group|
|Treatment Success on Day 29||80.7% n = 134|
88 of 101 dogs with AVVI
20 of 33 dogs with DCM
|76.3% n = 131|
77 of 100 dogs with AVVI
23 of 31 dogs with DCM
|Treatment Success on Day 56||71.1% n = 113|
66 of 85 dogs with AVVI
13 of 28 dogs with DCM
|67.2% n = 110|
56 of 85 dogs with AVVI
17 of 25 dogs with DCM
|No increase in furosemide dose between Day 1 and Day 29||78.3% n = 130||68.6% n = 126|
At the end of the 56-day study, dogs in the Vetmedin group were enrolled in an unmarked field study to monitor safety under extended use, without restrictions on concurrent dog medications.
Vetmedin, pet medicine was used safely in dogs concurrently receiving furosemide, digoxin, enalapril, atenolol, spironolactone, nitroglycerin, hydralazine, diltiazem, antiparasitic products (including heartworm prevention), antibiotics (metronidazole, cephalexin, amoxicillin-clavulanate, fluoroquinolones), topical ophthalmic and otic products, famotidine, theophylline, levothyroxine sodium, diphenhydramine, hydrocodone, metoclopramide, and butorphanol, and in dogs on sodium-restricted diets.
In a laboratory study, the palatability of Vetmedin pet med was evaluated in 20 adult female Beagle dogs offered doses twice daily for 14 days. Ninety percent (18 of 20 dogs) voluntarily consumed more than 70% of the 28 tablets offered. Including two dogs that consumed only 4 and 7% of the chewable tablets for dogs offered, the average voluntary consumption was 84.2%.
In a laboratory study, Vetmedin chewable tablets for dogs were administered to 6 healthy Beagles per treatment group at 0 (control), 1, 3, and 5 times the recommended dosage for 6 months.
Incidence of Cardiac Pathology/Histopathology in the Six-month Safety Study:
|Severe left ventricular hypertrophy with multifocal subendocardial ischemic lesions||One 3X and two 5X dogs|
|Moderate to marked myxomatous thickening of the mitral valves||Three 5X dogs|
|Myxomatous thickening of the chordae tendineae||One 3X and two 5X dogs|
|Endocardial thickening of the left ventricular outflow tract||One 1X, two 3X, and two 5X dogstd>|
|Endocardial thickening of the left ventricular outflow tract||One 1X, two 3X, and two 5X dogs|
|Left atrial endocardial thickening (jet lesions) in 2 of the dogs that developed murmurs of mitral valve insufficiency||One 3X and one 5X dog|
|Granulomatous inflammatory lesion in the right atrial myocardium||One 3X dog|
Store this heart medicine for dogs at controlled room temperature 59-86°F (15-30°C)
Vetmedin® (pimobendan) Chewable Tablets:
Available as Vetmedin 1.25 or Vetmedin 5 mg oblong half-scored chewable tablets for dogs – 50 tablets per bottle.
Manufactured by: MEDA Manufacturing GmbH, Cologne, Germany
Manufactured for: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506 U.S.A.